EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Branched-Chain Amino Acid Supplementation and Clinical Outcomes in Liver Cirrhosis: A Propensity Score-Matched Multicenter Retrospective Cohort Study

Mohammad Aldiabat, Yazan Aljabiri, Wesam Aleyadeh, Mahmoud Y Madi, Wing-Kin Syn, Kamran Qureshi

Digestive Diseases and Sciences · 2026

DOI: 10.1007/s10620-025-09258-7 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive Diseases and Sciences, 2026. Verfasst von Mohammad Aldiabat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA. Hauptthemen laut MEDLINE: Amino Acids, Branched-Chain, Liver Cirrhosis, Dietary Supplements. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Branched-Chain Amino Acid (BCAA) supplementation has shown benefits in reducing liver cirrhosis complications, improving survival, and potentially lowering hepatocellular carcinoma risk, but evidence on long-term outcomes remains limited. This real-world study evaluates clinical outcomes of liver cirrhosis patients receiving BCAA supplementation. METHODS: This retrospective cohort study used the TriNetX US Collaborative Network to identify liver cirrhosis patients aged ≥ 18 years, stratified by BCAA supplementation after diagnosis. Propensity score matching (PSM) balanced cohorts by demographics, body mass index, Model for End-Stage Liver Disease (MELD) score components, and baseline history of cirrhosis complications, including hepatic encephalopathy (HE), sarcopenia, spontaneous bacterial peritonitis (SBP), acute kidney injury (AKI), and falls. Composite and individual outcomes within 5 years were assessed using odds ratios (OR) with 95% confidence intervals (CI). RESULTS: Among 2,176 matched patients per group, BCAA supplementation was associated with lower rates of the composite outcome (OR 0.81, 95% CI: 0.71-0.92), HE (OR 0.63, 95% CI: 0.49-0.79), SBP (OR 0.77, 95% CI: 0.60-0.99), falls (OR 0.64, 95% CI: 0.53-0.78), all-cause emergency room visits (OR 0.56, 95% CI: 0.50-0.64), and hospitalizations (OR 0.68, 95% CI: 0.60-0.76). Liver transplantation occurred more frequently in the BCAA group (OR 1.49, 95% CI: 1.08-2.06). Sarcopenia rates were similar (OR 1.00, 95% CI: 0.42-2.41), while AKI was slightly more frequent (OR 1.13, 95% CI: 1.00-1.28). Subgroup analysis showed greater benefit in viral hepatitis-associated (OR 0.69, 95% CI: 0.53-0.90) and alcohol-associated cirrhosis (OR 0.73, 95% CI: 0.60-0.89), compared to MASLD (OR 0.81, 95% CI: 0.60-1.08). CONCLUSION: BCAA supplementation was associated with significant reductions in several cirrhosis-related complications, with most benefits observed in viral hepatitis-associated and alcohol-associated cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amino Acids, Branched-ChainLiver CirrhosisDietary SupplementsHumansMaleFemaleRetrospective StudiesMiddle AgedPropensity ScoreAgedTreatment OutcomeHepatic Encephalopathy

Stichwörter der Autor:innen

Branched-chain amino acidsClinical outcomesComplicationsLiver cirrhosisLiver transplantation

Substanzen

Amino Acids, Branched-Chain

Autor:innen und Institutionen

  • Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA.
  • Department of Medicine, Washington University in St Louis, St Louis, MO, USA.
  • Department of Medicine, Cleveland Clinic Akron General Hospital, Akron, OH, USA.
  • Division of Gastroenterology and Hepatology, Saint Louis University, 1225 S Grand Blvd 3L - Door 1-2, St. Louis, MO, 63104, USA.
  • Department of Physiology, Faculty of Medicine and Nursing, University of Basque Country UPV/EHU, Vizcaya, Spain.
  • Division of Gastroenterology and Hepatology, Saint Louis University, 1225 S Grand Blvd 3L - Door 1-2, St. Louis, MO, 63104, USA. kamran.qureshi@slucare.ssmhealth.com.

Zitieren

APA

Aldiabat, M., Aljabiri, Y., Aleyadeh, W., Madi, M. Y., Syn, W. K., & Qureshi, K. (2026). Branched-Chain Amino Acid Supplementation and Clinical Outcomes in Liver Cirrhosis: A Propensity Score-Matched Multicenter Retrospective Cohort Study. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-025-09258-7

Vancouver

Aldiabat M, Aljabiri Y, Aleyadeh W, Madi MY, Syn WK, Qureshi K. Branched-Chain Amino Acid Supplementation and Clinical Outcomes in Liver Cirrhosis: A Propensity Score-Matched Multicenter Retrospective Cohort Study. Digestive Diseases and Sciences. 2026. doi:10.1007/s10620-025-09258-7

BibTeX
@article{Aldiabat2026,
  author = {Aldiabat, Mohammad and Aljabiri, Yazan and Aleyadeh, Wesam and Madi, Mahmoud Y and Syn, Wing-Kin and Qureshi, Kamran},
  title = {Branched-Chain Amino Acid Supplementation and Clinical Outcomes in Liver Cirrhosis: A Propensity Score-Matched Multicenter Retrospective Cohort Study},
  journal = {Digestive Diseases and Sciences},
  year = {2026},
  doi = {10.1007/s10620-025-09258-7}
}
Kostenlos starten →